from press. .. . A one-on-one tango has since turned into a full-on hoedown as several major pharmaceutical companies continue to change partners on the M&A floor, with Valeant Pharmaceuticals and Pershing Square Capital Management reportedly upping their bid Tuesday for Allergan by $15 per share, according to the Wall Street Journal. The new bid would raise Valeant's bid to about 191 a share. Allergan rose 2% in late trading to 190.20, extending regular session gains on other news. But which pharmaceutical firm will ultimately win "Dancing With The Drugmakers" remains to be seen.... Reuters sources, who reportedly said that Allergan would consider an offer of more than $200 a share
Allergan put that $200/share price out there because they know Valeant will be hard pressed to meet that price. Valeant is tapped out in the borrowing arena. Time to go home boys!! A friendlier Activis is in town.
Exactly last post, the accounting games are over boys on top! Plan B Whoops wHat's that I hear, oh you don't have one! TITANIC peeps I'm afraid